TRML (Tourmaline Bio Inc) Net Profit

TRML (Tourmaline Bio) - company brandmark

Tourmaline Bio, Inc. (TRML) is a biotech company utilizing an asset-light model where antibody production is outsourced to third-party contractors. The price history on the GURU.Markets chart, where the indicator is -0.09, reflects the asset's dynamics. The business is currently spending massive sums on new drug trials, relying on debt capital. Meanwhile, the firm must contend with expansion from industry behemoths and the risk of therapy devaluation due to generics.

TRML (Tourmaline Bio, Inc.) Net Profit history from 02/21/2024 to 11/08/2025

Analytical breakdowns and data insights for company Tourmaline Bio (TRML)

- price and consensus price forecast:
Stock Quotes Tourmaline|TRML - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Tourmaline|TRML - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Tourmaline Bio|TRML - Book Capitalization|Market Capitalization to Book Value tourmalinebio.com|TRML - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Tourmaline Bio, Inc.|TRML - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Tourmaline Bio Inc|TRML - Company Total Debt|Debts to Book Capitalization Tourmaline|TRML - Company Long-Term Debt|Company Short-Term Indebtedness Tourmaline Bio|Immediate Liquidity tourmalinebio.com
- net income and valuation multiples indicators:
TRML - Net Income
Summary company analysis:Tourmaline Bio, Inc.
Core merchandise of Tourmaline Corp

Tourmaline Bio, Inc. (TRML) specializes in repurposing IL-6 antibodies for inelastic demand therapies in ophthalmology and cardiology. This indicator captures net income per share, reflecting the final balance of market forces. It is critical for investors to evaluate this metric as confirmation of the effectiveness of the monetization strategy for future pricing power. A positive trend signals an increase in fundamental value. The dynamics of the company's financial results allow for the timely identification of the industry cycle phase.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Precigen Inc (PGEN) - Company Net Income|PHAR: Net Income|Nektar Corp - Profit After Payment of Taxes|Upstream Bio Inc (UPB) - Company Net Income|Company Net Income zenasbio.com (ZBIO)|Net Income IMNM|Net Profit Gossamer Bio Inc|Company Net Income KalVista Pharmaceuticals Inc (KALV)|SEPN (Septerna Pharma) - Final Profit|Company Net Income Pieris Pharmaceuticals PVLA|SVRA - Net Income|Rigel Pharmaceuticals, Inc. - Net Profit|ANAB - Net Profit|Astria Pharma (ATXS) - Company Net Income|ENGN (enGene Corp) - Company Net Income|RAPT (RAPT Therapeutics, Inc.) - Net Profit|Aerovate (JBIO) - Net Financial Result|Company Net Income Aclaris Therapeutics, Inc. (ACRS)|Kyverna Therapeutics Inc. - Company Profit|Net Profit TLSA (Tiziana Life Sciences PLC)|Cabaletta Bio Inc (CABA) - Company Net Income|VTYX: Net Income|Final Profit THTX (theratech.com)|AVTX: Net Profit|ELDN (Eledon Pharmaceuticals Inc.) - Company Net Income|AGEN (Agenus Inc) - Net Profit|Climb Bio, Inc (CLYM) - Net Financial Result|Company Net Income Zura Bio Limited (ZURA)|ATYR - Company Net Income|Adagene Inc. - Net Income|Final Profit IMA|Shattuck Therapeutics - Net Profit|Net Financial Result Equillium, Inc. EQ|connectbiopharm.com (CNTB) - Company Net Income|Company Profit IMUX|ATRA (Atara Biotherapeutics, Inc.) - Net Profit|Net Income InflaRx GmbH (IFRX)|Net Income XFOR (X4 Pharma)|Net Financial Result adicetbio.com|Celularity - Net Income|Profit After Payment of Taxes INMB (inmunebio.com)|BRNS - Company Net Income|Final Profit KZR (Kezar Life Sciences Inc.)|SAB Biotherapeutics, Inc (SABS) - Company Net Income|Net Income Akari Therapeutics, Plc|Company Net Income Enlivex Therapeutics Ltd|Company Net Income QTTB|Company Net Income GeoVax (GOVX)|EDSA: Profit After Tax|Net Profit IBIO (iBio Corp)|Final Profit CARM|XTL Biopharmaceuticals - Net Profit|BOLT - Net Profit|hcwbiologics.com (HCWB) - Company Net Income|Aptevo Therapeutics Inc. - Final Profit|Company Net Income AIM ImmunoTech|Net Income Aditxt Corp (ADTX)|Net Profit GRI|Net Profit xortx.com (XRTX)|Vyome Holdings - Net Income|Final Profit REVB|Indaptus - Net Profit|Net Financial Result BiondVax Pharmaceuticals SCNI|calcimedica.com (CALI) - Company Net Income|Net Income Affimed N.V.|Company Net Income Allakos Inc|Net Income HOOKIPA (HOOK)|Net Income IGMS (IGM Biosciences, Inc.)|Net Profit iTeos Pharma (ITOS)|Company Net Income Ocean Biomedical, Inc. OCEA|TCBP: Company Profit|Third Harmonic Bio, Inc. - Net Profit